Familial hypercholesterolaemia: A model of care for Australasia

Familial hypercholesterolaemia (FH) is a dominantly inherited disorder present from birth that causes marked elevation in plasma cholesteroland premature coronary heart disease. There are at least 45,000 people with FH in Australia and New Zealand, but the vast majority remainsundetected and those d...

Full description

Bibliographic Details
Main Authors: Watts, G., Sullivan, D., Poplawski, N., Van Bockxmeer, F., Hamilton-Craig, I., Clifton, P., O'Brien, R., Bishop, W., George, P., Barter, P., Bates, T., Burnett, J., Coakley, J., Davidson, Patricia, Emery, J., Martin, A., Farid, W., Freeman, L., Geelhoed, E., Juniper, A., Kidd, A., Kostner, K., Krass, I., Livingston, M., Maxwell, Susannah, O'Leary, Peter, Owaimrin, A., Redgrave, T., Reid, N., Southwell, L., Suthers, G., Tonkin, A., Towler, Simon, Trent, R.
Format: Journal Article
Published: Elseiver Ireland Ltd 2011
Subjects:
Online Access:http://hdl.handle.net/20.500.11937/49291
_version_ 1848758208177373184
author Watts, G.
Sullivan, D.
Poplawski, N.
Van Bockxmeer, F.
Hamilton-Craig, I.
Clifton, P.
O'Brien, R.
Bishop, W.
George, P.
Barter, P.
Bates, T.
Burnett, J.
Coakley, J.
Davidson, Patricia
Emery, J.
Martin, A.
Farid, W.
Freeman, L.
Geelhoed, E.
Juniper, A.
Kidd, A.
Kostner, K.
Krass, I.
Livingston, M.
Maxwell, Susannah
O'Leary, Peter
Owaimrin, A.
Redgrave, T.
Reid, N.
Southwell, L.
Suthers, G.
Tonkin, A.
Towler, Simon
Trent, R.
author_facet Watts, G.
Sullivan, D.
Poplawski, N.
Van Bockxmeer, F.
Hamilton-Craig, I.
Clifton, P.
O'Brien, R.
Bishop, W.
George, P.
Barter, P.
Bates, T.
Burnett, J.
Coakley, J.
Davidson, Patricia
Emery, J.
Martin, A.
Farid, W.
Freeman, L.
Geelhoed, E.
Juniper, A.
Kidd, A.
Kostner, K.
Krass, I.
Livingston, M.
Maxwell, Susannah
O'Leary, Peter
Owaimrin, A.
Redgrave, T.
Reid, N.
Southwell, L.
Suthers, G.
Tonkin, A.
Towler, Simon
Trent, R.
author_sort Watts, G.
building Curtin Institutional Repository
collection Online Access
description Familial hypercholesterolaemia (FH) is a dominantly inherited disorder present from birth that causes marked elevation in plasma cholesteroland premature coronary heart disease. There are at least 45,000 people with FH in Australia and New Zealand, but the vast majority remainsundetected and those diagnosed with the condition are inadequately treated.To bridge this major gap in coronary prevention the FH Australasia Network (Australian Atherosclerosis Society) has developed a consensusmodel of care (MoC) for FH. The MoC is based on clinical experience, expert opinion, published evidence and consultations with a widespectrum of stakeholders, and has been developed for use primarily by specialist centres intending starting a clinical service for FH. This MoCaims to provide a standardised, high-quality and cost-effective system of care that is likely to have the highest impact on patient outcomes.The MoC for FH is presented as a series of recommendations and algorithms focusing on the standards required for the detection, diagnosis,assessment and management of FH in adults and children. The process involved in cascade screening and risk notification, the backbonefor detecting new cases of FH, is detailed. Guidance on treatment is based on risk stratifying patients, management of non-cholesterol riskfactors, safe and effective use of statins, and a rational approach to follow-up of patients. Clinical and laboratory recommendations are givenfor genetic testing. An integrative system for providing best clinical care is described.This MoC for FH is not prescriptive and needs to be complemented by good clinical judgment and adjusted for local needs and resources.After initial implementation, the MoC will require critical evaluation, development and appropriate modification.
first_indexed 2025-11-14T09:40:20Z
format Journal Article
id curtin-20.500.11937-49291
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T09:40:20Z
publishDate 2011
publisher Elseiver Ireland Ltd
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-492912018-04-19T01:15:34Z Familial hypercholesterolaemia: A model of care for Australasia Watts, G. Sullivan, D. Poplawski, N. Van Bockxmeer, F. Hamilton-Craig, I. Clifton, P. O'Brien, R. Bishop, W. George, P. Barter, P. Bates, T. Burnett, J. Coakley, J. Davidson, Patricia Emery, J. Martin, A. Farid, W. Freeman, L. Geelhoed, E. Juniper, A. Kidd, A. Kostner, K. Krass, I. Livingston, M. Maxwell, Susannah O'Leary, Peter Owaimrin, A. Redgrave, T. Reid, N. Southwell, L. Suthers, G. Tonkin, A. Towler, Simon Trent, R. cascade screening model of care treatment Familial hypercholesterolaemia adolescents diagnosis adults children genetic testing assessment Familial hypercholesterolaemia (FH) is a dominantly inherited disorder present from birth that causes marked elevation in plasma cholesteroland premature coronary heart disease. There are at least 45,000 people with FH in Australia and New Zealand, but the vast majority remainsundetected and those diagnosed with the condition are inadequately treated.To bridge this major gap in coronary prevention the FH Australasia Network (Australian Atherosclerosis Society) has developed a consensusmodel of care (MoC) for FH. The MoC is based on clinical experience, expert opinion, published evidence and consultations with a widespectrum of stakeholders, and has been developed for use primarily by specialist centres intending starting a clinical service for FH. This MoCaims to provide a standardised, high-quality and cost-effective system of care that is likely to have the highest impact on patient outcomes.The MoC for FH is presented as a series of recommendations and algorithms focusing on the standards required for the detection, diagnosis,assessment and management of FH in adults and children. The process involved in cascade screening and risk notification, the backbonefor detecting new cases of FH, is detailed. Guidance on treatment is based on risk stratifying patients, management of non-cholesterol riskfactors, safe and effective use of statins, and a rational approach to follow-up of patients. Clinical and laboratory recommendations are givenfor genetic testing. An integrative system for providing best clinical care is described.This MoC for FH is not prescriptive and needs to be complemented by good clinical judgment and adjusted for local needs and resources.After initial implementation, the MoC will require critical evaluation, development and appropriate modification. 2011 Journal Article http://hdl.handle.net/20.500.11937/49291 10.1016/j.atherosclerosissup.2011.06.001 Elseiver Ireland Ltd restricted
spellingShingle cascade screening
model of care
treatment
Familial hypercholesterolaemia
adolescents
diagnosis
adults
children
genetic testing
assessment
Watts, G.
Sullivan, D.
Poplawski, N.
Van Bockxmeer, F.
Hamilton-Craig, I.
Clifton, P.
O'Brien, R.
Bishop, W.
George, P.
Barter, P.
Bates, T.
Burnett, J.
Coakley, J.
Davidson, Patricia
Emery, J.
Martin, A.
Farid, W.
Freeman, L.
Geelhoed, E.
Juniper, A.
Kidd, A.
Kostner, K.
Krass, I.
Livingston, M.
Maxwell, Susannah
O'Leary, Peter
Owaimrin, A.
Redgrave, T.
Reid, N.
Southwell, L.
Suthers, G.
Tonkin, A.
Towler, Simon
Trent, R.
Familial hypercholesterolaemia: A model of care for Australasia
title Familial hypercholesterolaemia: A model of care for Australasia
title_full Familial hypercholesterolaemia: A model of care for Australasia
title_fullStr Familial hypercholesterolaemia: A model of care for Australasia
title_full_unstemmed Familial hypercholesterolaemia: A model of care for Australasia
title_short Familial hypercholesterolaemia: A model of care for Australasia
title_sort familial hypercholesterolaemia: a model of care for australasia
topic cascade screening
model of care
treatment
Familial hypercholesterolaemia
adolescents
diagnosis
adults
children
genetic testing
assessment
url http://hdl.handle.net/20.500.11937/49291